SCHEDULE: T. Rowe Price Boosts Alkermes Stake to 6.1%

T. Rowe Price Associates, Inc. has reported a 6.1% beneficial ownership stake in Alkermes PLC, holding over 10 million common shares.

Summary

• T. Rowe Price Associates, Inc. reported beneficial ownership of 10,041,900 common shares of Alkermes PLC.
• This ownership represents 6.1% of Alkermes PLC's common stock.
• T. Rowe Price holds sole voting power over 9,983,207 shares and sole dispositive power over all 10,041,900 shares.
• The filing is an Amendment No. 1 to a Schedule 13G, indicating a change from a previous filing.
• The investment is held in the ordinary course of business and not for the purpose of changing or influencing control of Alkermes PLC.

Sentiment

Score: 7

Explanation: The filing indicates a significant passive investment by a reputable institutional investor, T. Rowe Price, in Alkermes PLC, suggesting a vote of confidence in the company's prospects.

Positives

• A major institutional investor, T. Rowe Price Associates, Inc., has disclosed a significant stake, indicating confidence in Alkermes PLC's prospects.
• T. Rowe Price holds substantial sole voting and dispositive power, suggesting active management of this passive investment.

Risks

• The investment is explicitly stated to be in the ordinary course of business and not for the purpose of changing or influencing control of the issuer, meaning T. Rowe Price will not actively push for strategic changes.

Future Outlook

This filing does not provide forward-looking statements or guidance from Alkermes PLC or T. Rowe Price regarding the issuer's future performance.

Industry Context

The disclosure of a significant stake by a prominent asset manager like T. Rowe Price in Alkermes PLC, a pharmaceutical company, highlights continued institutional interest and investment in the healthcare and biotechnology sectors.

Stakeholder Impact

• Shareholders: Increased institutional ownership by a reputable firm like T. Rowe Price may be perceived positively, potentially contributing to market stability and investor confidence.

Key Dates

Recommendation

The filing indicates a substantial passive investment by T. Rowe Price Associates, Inc. in Alkermes PLC, reflecting institutional confidence. While not an active control-seeking stake, the significant ownership by a major asset manager suggests a positive long-term view, warranting a 'hold' recommendation for existing investors.

Keywords

Alkermes PLC, T. Rowe Price, institutional ownership, beneficial ownership, common stock, investment adviser, pharmaceutical, biotechnology, Schedule 13G